Key Highlights

  • Shares are trading 13.78% higher at USD 6.44 on Thursday, October 29, 2026, pointing to a prior close of about USD 5.66 (calculated).
  • The ULTRA-Peds Registry followed 91 children at seven hospitals, and 87% survived the treatment course.
  • The company intends to seek a label from 5 kg, compared with 20 kg at present.
  • Second-quarter 2026 revenue was $2.0 million, up 14%, with a 76% gross margin.
  • Cash stood near $8.8 million at August 31, 2026, enough to fund operations into the third quarter of 2027.

Nuwellis Stock Rise: What Sits Behind a 13.78% Gain With No October 29 Release?

Nuwellis (NASDAQ:NUWE) shares are trading 13.78% higher at USD 6.44 on Thursday, October 29, 2026, which points to a prior close of about USD 5.66 (calculated). No company announcement dated October 29 accompanied the advance.

The latest release, on Tuesday, October 27, 2026, said a multicenter pediatric study of the Aquadex system had been published in a medical journal. Nuwellis makes Aquadex, a device that clears excess fluid from patients with fluid overload, and is developing the Vivian continuous renal replacement therapy system for children as small as 2.5 kg.

ULTRA-Peds Registry Findings: What Do They Show for Very Small Patients?

The ULTRA-Peds Registry covered 91 patients at seven hospitals. About 62% weighed under 10 kg, 41 weighed less than 5 kg, and 87% survived the treatment course.

The company plans to use the data to back a labeling expansion down to 5 kg from today's 20 kg threshold. The release gives no filing date, and regulatory approval is not assured.

Nuwellis Results: Can a 76% Gross Margin Cushion a $4.8 Million Quarterly Loss?

In its release of Thursday, August 13, 2026, Nuwellis posted second-quarter revenue of $2.0 million, up 14%, and first-half revenue of $4.4 million, up 20%. Operating expenses were $4.7 million, and the net loss of $4.8 million included $1.7 million of non-cash warrant valuation expense. A company update on September 9 put second-quarter gross margin at 76%, versus 56% a year earlier.

Cash was $3.9 million at June 30, 2026, following about $12.7 million of gross financing in June and July. An update on September 17 said 31 Aquadex SmartFlow consoles had been sold so far this year and first-half U.S. revenue grew 26%.

Leadership and Distribution: What Has Changed at Nuwellis This Year?

A new president and chief executive officer took the role on June 30, 2026. On August 25, 2026 the company signed a staged co-promotion and distribution agreement with Atrility Medical for the AtriAmp device, starting with a six-month pilot across three sales territories.

The company gives no formal financial guidance, and with the cash runway ending in the third quarter of 2027, further financing remains possible.

What to Watch Next: Vivian Advisory Board Meeting and Third-Quarter Results

Nuwellis will convene a pediatric Medical and Nursing Advisory Board on Wednesday, November 18 and Thursday, November 19, 2026, bringing about a dozen providers from 11 U.S. pediatric institutions to guide Vivian development. Other items to follow include any FDA submission on the Aquadex label, third-quarter 2026 results and new financing.